Loading...

Secular Trends And Cell Therapies Will Expand Markets Despite Risks

Published
17 Apr 25
Updated
07 May 25
AnalystHighTarget's Fair Value
US$17.65
24.1% undervalued intrinsic discount
10 Sep
US$13.40
Loading
1Y
-45.9%
7D
-6.2%

Author's Valuation

US$17.6524.1% undervalued intrinsic discount

AnalystHighTarget Fair Value

Shared on07 May 25
Fair value Decreased 27%

Shared on30 Apr 25
Fair value Decreased 15%

AnalystHighTarget has decreased future PE multiple from 32.7x to 28.8x.

Shared on23 Apr 25
Fair value Increased 16%

AnalystHighTarget made no meaningful changes to valuation assumptions.